Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the
combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.